IN THIS ISSUE

Ed Silverman
Coverage of this costly biologic for prostate cancer is generally being provided under very specific circumstances
John Carroll
Not only is the program expected to be short on cash, but many patients may not be able to afford even the subsidized rates
Q&A
He started blogging to get information out to physicians; now he believes that patients too will benefit greatly from e-mail, blogs, tweets, and the like
Frank Diamond
Bracing for an influx of enrollees, medical managers at some plans take creative approaches to fixing a decades-old problem
Emad Rizk, MD
When we truly begin to manage the person and not the condition, there will be payoffs on both the cost and quality fronts
Legislation & Regulation
John Carroll
Health reform requires a uniform process for member appeals, and the NAIC approach has been adopted by the Department of Health and Human Services
Plan Watch
Frank Diamond
Emblem Health is starting slowly with an effort that demographics nearly guarantee will catch on in New York and across the country
Tomorrow's Medicine
Thomas Morrow, MD
Biotechnology companies are doing promising work in producing new organs, with one adult stem cell therapy standing a good chance of approval in Canada
News and Commentary
News and Commentary
News and Commentary
News and Commentary